NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
26 Maggio 2021 - 10:15PM
Business Wire
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the
‘‘Company’’), a late-clinical stage biotechnology company
pioneering physics-based approaches to expand treatment
possibilities for patients with cancer, today announced that
Laurent Levy, co-founder and chief executive officer, will discuss
the Company’s latest corporate and clinical developments in a
fireside chat at the Jefferies Virtual Healthcare Conference on the
4th of June at 8:00 AM Eastern Time (14:00 Central European
Time).
A live webcast of the discussion, as well as an archived
recording may be accessed by visiting the events section of the
Company’s website.
***
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company
pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients;
supported by people committed to making a difference for humanity.
The company’s philosophy is rooted in the concept of pushing past
the boundaries of what is known to expand possibilities for human
life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France, and has subsidiaries in Cambridge, Massachusetts (United
States) as well as France, Spain, and Germany. Nanobiotix has been
listed on Euronext: Paris since 2012 and on the Nasdaq Global
Select Market in New York City in December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The Company’s resources are primarily devoted to the development of
its lead product candidate–NBTXR3—which is th eproduct of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210526006020/en/
Nanobiotix
Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com
Investor Relations Department Kate McNeil SVP, Investor
Relations +1 (609) 678-7388 investors@nanobiotix.com
Media Relations
France – Ulysse Communication Pierre-Louis Germain + 33
(0) 6 64 79 97 51 plgermain@ulysse-communication.com
US – Porter Novelli Stefanie Tuck +1 (917) 390-1394
Stefanie.tuck@porternovelli.com
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Nanobiotix (EU:NANO)
Storico
Da Apr 2023 a Apr 2024